ERBB2 and breast carcinoma: TNBC accounts for 10–15% of all breast cancer cases and, due to the lack of estrogen/progesterone receptors (ER/PR) and the low-level expression of human epidermal growth factor receptor 2 (HER2), does not respond to hormonal or anti-HER2 therapies [3].